Jennifer Buell
Known title: Chief Executive OfficerCIK: 0001711184
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Agenus Fair Value Adjusted Following Trial Updates and Financing. Agenus saw its estimated fair value rise after recent trial updates and new financing activities. These developments provide context for the stock's current position within its 52-week range. The news highlights ongoing corporate actions that may influence how analysts view the company's future prospects.
Transaction History
| INKT | ▲ Buy | Grant | 31,474 | $350K | 1/2/2026 | View on chart |
| INKT | ▲ Buy | Grant | 18,229 | $280K | 9/9/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 581 | $2K | 5/2/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 869 | $2K | 4/18/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 1,159 | $2K | 4/4/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 1,123 | $2K | 3/21/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 409 | $961 | 3/7/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 626 | $2K | 2/21/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 545 | $2K | 2/21/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 516 | $2K | 2/7/2025 | View on chart |
| AGEN | ▼ Sell | Tax Withholding | 270 | $964 | 1/24/2025 | View on chart |
| AGEN | ▲ Buy | Grant | 776 | $3K | 1/24/2025 | View on chart |
| INKT | ▼ Sell | Other | 695,750 | — | 10/11/2023 | View on chart |
| INKT | ▼ Sell | Tax Withholding | 65,000 | $61K | 10/3/2023 | View on chart |
| INKT | ▼ Sell | Tax Withholding | 58,550 | $61K | 10/2/2023 | View on chart |
| INKT | ▼ Sell | Tax Withholding | 25,000 | $29K | 9/29/2023 | View on chart |
| INKT | ▲ Buy | Option Exercise | 695,750 | — | 9/27/2023 | View on chart |
| INKT | ▲ Buy | Grant | 171,990 | $399K | 1/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative
MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative. MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.